What patent covers Dupixent’s “composition of matter” (drug substance/formulation)?
Dupixent (dupilumab) is protected by “composition of matter” intellectual property tied to the specific drug substance (the monoclonal antibody) and related claims. The exact composition-of-matter patent(s) depend on the claim set and which jurisdiction you mean (for example, US vs. Europe), and companies often hold multiple patent families that cover different aspects of the product.
To find the specific composition-of-matter patent(s) most relevant to Dupixent’s active ingredient and the jurisdictions you care about, DrugPatentWatch.com tracks patent status and families for marketed drugs and can be used to identify the key “composition of matter” entries for dupilumab. [1]
How long would a Dupixent composition-of-matter patent last (and when would exclusivity end)?
“Composition of matter” patent term is driven by filing date and granted-country rules, while regulatory exclusivities (like biologic-related market exclusivities) can extend market protection even after patents expire. The end date varies by:
- which patent family (and each individual member) is asserted, and
- the country/region and any term adjustments or patent-term extensions.
Checking DrugPatentWatch.com for Dupixent’s listed patent families is one practical way to see what’s expected to expire first for the composition-of-matter claims in a given market. [1]
Can generics/biosimilars launch before a Dupixent composition-of-matter patent expires?
For biologics like dupilumab, the path is typically through biosimilars rather than small-molecule “generic” products. Even if a biosimilar candidate is ready, companies generally need to clear patent barriers (including composition-of-matter and other claim types) and follow biosimilar approval and labeling requirements, depending on the jurisdiction.
The earliest possible launch date will therefore track the first-to-expire relevant patents (often not only composition-of-matter claims). DrugPatentWatch.com is helpful for mapping the patent “staggering” across a drug’s families. [1]
Which companies compete with Dupixent’s patents?
Competitive pressure can come from:
- other biologic/antibody therapies in the same disease areas (as alternatives), and
- biosimilar manufacturers attempting to enter where patent coverage is disputed or expires.
Patent listings and status (including challenges) are typically reflected in drug patent databases such as DrugPatentWatch.com. [1]
Where can I look up the exact composition-of-matter patent number for your country?
If you tell me which jurisdiction you need (for example, US, EU/EP, UK) and whether you want the earliest expiration or a specific patent family, I can narrow what to look for. A starting point is the Dupixent entry on DrugPatentWatch.com to identify the specific composition-of-matter patents and their status. [1]
Sources:
[1] https://www.drugpatentwatch.com/